디티앤씨알오
383930KOSDAQ50.8 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
DT&CR is a Full-Service CRO providing non-clinical and clinical trial services across pharmaceuticals, medical devices, and health functional foods, offering integrated solutions from early-stage drug development to FDA approval. In 2025, revenue increased by 32.7% year-over-year to 47.7 billion won, driven by specialized services such as the expanded PK/PD center, which scientifically analyzes drug candidate characteristics.
Number of Employees
314people
Average Salary
47.4M KRW
Score Calculation Basis
Detailed Financial Score
Lower than industry avg (good)
Well below industry avg
Lower than industry avg (good)
Avg ▲34.0% (2-year basis)
Avg ▲28.0% (2-year basis)
Avg ROE -19.9% (improving, 3yr)
Detailed News Sentiment
- Negative디티앤씨알오, CB 전환가 반년 만에 최저한도까지 '뚝'
디티앤씨알오의 CB 전환가액이 하락하여 투자자들의 불안감을 증가시켰다.
Detailed Momentum
Near 52w low (3%, downtrend)
1m -17.01% (strong drop)
Volume flat
Detailed Disclosure
- Neutral신주인수권행사가액의조정2026-08-20
- Neutral전환가액의조정2026-08-20
- Neutral[기재정정]전환가액의조정2026-08-20
- Neutral신주인수권행사가액의조정2026-08-20
- Neutral반기보고서 (2026.06)2026-08-14
